Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00261417
Status:
TERMINATED
Last Update Posted:
2009-04-22
First Post:
2005-12-01
Brief Title:
Dose Response Study in Japanese Patients
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-Blind Multicentre Placebo-Controlled Study to Evaluate the Efficacy Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes
Status:
TERMINATED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The development program has been terminated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 12-week study to determine the effect on glucose and lipids safety and tolerability of four doses of tesaglitazar 025 05 075 and 1 mg compared with placebo in patients with type 2 diabetes Improvement in dyslipidemia will be evaluated The study comprises a 2-week screening period 4-week placebo run-in a 12-week randomized double blind parallel group multi-center placebo-controlled treatment period and a 3-week follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SH-SBD-0013 | None | None | None |